nevirapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antivirals 1904 129618-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nevirapine hemihydrate
  • nevirapine
  • viramune
  • nevarapine
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
  • Molecular weight: 266.30
  • Formula: C15H14N4O
  • CLOGP: 2.72
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 58.12
  • ALOGS: -3.41
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.46 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.32 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 53 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.601 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.766 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 74.473 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.818 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 42.910 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 72.730 % High 1
herg hERG pIC50 4.132 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 0.931 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.155 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 47.810 % High 1
kinase-safety-class ACVR2B,AXL,CAMK2D,CDK9,EIF2AK3,ERBB2,FLT3,GRK2,IRAK1,ITK,KIT,MAP3K21,NTRK1,PDK1,PDK2,PDK4,PRKDC 17
kinase-selectivity-class ACVR2B,AURKC,AXL,BRAF,CAMK2D,CDK9,EIF2AK3,ERBB2,HASPIN,IRAK1,MAP3K10,MAP3K11,MAP3K21,MARK4,SIK2,STK33,TTK,ULK1 18
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.170 High 1
mh-clint Mouse hepatocyte intrinsic clearance 11.614 High 1
mppb Mouse plasma protein binding (% unbound) 46.490 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.499 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1
pppb Pig plasma protein binding (% unbound) 64.540 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.890 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.910 % High 1
rppb Rat plasma protein binding (% unbound) 40.390 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 331.131 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 21, 1996 FDA BOEHRINGER INGELHEIM
Feb. 4, 1998 EMA Boehringer Ingelheim International GmbH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 804.85 36.70 225 6846 30224 90591152
Viral mutation identified 791.32 36.70 137 6934 1888 90619488
Virologic failure 685.58 36.70 123 6948 2101 90619275
Foetal exposure during pregnancy 538.53 36.70 179 6892 42796 90578580
Pathogen resistance 387.33 36.70 96 6975 8019 90613357
Stillbirth 334.92 36.70 84 6987 7359 90614017
Exposure during pregnancy 315.34 36.70 208 6863 238202 90383174
Maternal exposure during pregnancy 257.28 36.70 217 6854 359846 90261530
Caesarean section 254.88 36.70 83 6988 18494 90602882
Abortion spontaneous 253.75 36.70 110 6961 53946 90567430
Pregnancy 217.46 36.70 103 6968 61944 90559432
Stevens-Johnson syndrome 206.93 36.70 80 6991 29296 90592080
Immune reconstitution inflammatory syndrome 190.08 36.70 53 7018 6966 90614410
Lipodystrophy acquired 175.85 36.70 37 7034 1477 90619899
Premature baby 161.44 36.70 64 7007 25013 90596363
Acquired gene mutation 135.65 36.70 29 7042 1250 90620126
Portal hypertension 120.45 36.70 34 7037 4667 90616709
Supernumerary nipple 112.45 36.70 16 7055 51 90621325
Acoustic stimulation tests abnormal 106.04 36.70 16 7055 84 90621292
Viral load increased 103.04 36.70 24 7047 1532 90619844
Congenital naevus 102.80 36.70 17 7054 173 90621203
Low set ears 96.15 36.70 17 7054 264 90621112
Abortion induced 89.46 36.70 34 7037 11854 90609522
Premature delivery 87.87 36.70 48 7023 38714 90582662
Ventricular septal defect 85.76 36.70 27 7044 5380 90615996
Immune reconstitution inflammatory syndrome associated tuberculosis 80.23 36.70 16 7055 487 90620889
Alanine aminotransferase increased 79.27 36.70 69 7002 118269 90503107
Postpartum sepsis 77.66 36.70 10 7061 10 90621366
CD4 lymphocytes decreased 77.27 36.70 19 7052 1528 90619848
Conjunctivalisation 76.13 36.70 9 7062 0 90621376
Mitochondrial toxicity 75.82 36.70 16 7055 647 90620729
Premature rupture of membranes 72.80 36.70 24 7047 5534 90615842
Blood HIV RNA increased 72.35 36.70 16 7055 808 90620568
Rash maculo-papular 72.11 36.70 43 7028 40890 90580486
Pre-eclampsia 70.37 36.70 28 7043 11020 90610356
Nephropathy toxic 69.99 36.70 29 7042 12659 90608717
Amniotic cavity infection 68.99 36.70 17 7054 1379 90619997
Toxic epidermal necrolysis 67.47 36.70 38 7033 32490 90588886
Malaria 67.01 36.70 12 7059 201 90621175
Maternal drugs affecting foetus 66.48 36.70 22 7049 5133 90616243
Hemivertebra 65.98 36.70 11 7060 118 90621258
Hydrops foetalis 65.57 36.70 14 7057 599 90620777
Aspartate aminotransferase increased 64.88 36.70 58 7013 102879 90518497
Lactic acidosis 61.46 36.70 42 7029 50421 90570955
Uveal prolapse 59.21 36.70 7 7064 0 90621376
Premature labour 58.69 36.70 26 7045 13350 90608026
Anaemia 58.21 36.70 101 6970 352701 90268675
Retinoblastoma 56.14 36.70 9 7062 74 90621302
Eyelid oedema 55.74 36.70 24 7047 11510 90609866
Eyelid scar 55.44 36.70 7 7064 5 90621371
Congenital choroid plexus cyst 55.37 36.70 11 7060 328 90621048
Foetal growth restriction 53.64 36.70 22 7049 9358 90612018
Hepatomegaly 52.42 36.70 24 7047 13302 90608074
Pulmonary tuberculosis 51.98 36.70 18 7053 4816 90616560
Fat tissue increased 51.45 36.70 12 7059 770 90620606
Foetal death 50.68 36.70 27 7044 20696 90600680
Low birth weight baby 50.07 36.70 21 7050 9446 90611930
Pain 49.67 36.70 9 7062 996332 89625044
Ulcerative keratitis 49.63 36.70 16 7055 3437 90617939
Drug reaction with eosinophilia and systemic symptoms 48.34 36.70 34 7037 42724 90578652
Hepatic cytolysis 48.09 36.70 30 7041 30886 90590490
Left ventricular dilatation 47.98 36.70 11 7060 654 90620722
Ultrasound antenatal screen 47.14 36.70 9 7062 217 90621159
Premature separation of placenta 46.82 36.70 14 7057 2348 90619028
Acute HIV infection 45.26 36.70 6 7065 9 90621367
Lipoatrophy 43.88 36.70 9 7062 316 90621060
Treatment noncompliance 42.56 36.70 34 7037 51693 90569683
Spinocerebellar disorder 42.44 36.70 6 7065 18 90621358
Proteinuria 42.40 36.70 25 7046 23266 90598110
Astrocytoma malignant 40.71 36.70 6 7065 26 90621350
Breast disorder 40.50 36.70 13 7058 2754 90618622
Live birth 39.15 36.70 39 7032 79068 90542308
Hyperlactacidaemia 39.12 36.70 14 7057 4122 90617254
HIV antibody positive 38.83 36.70 5 7066 5 90621371
Conjunctival hyperaemia 38.77 36.70 13 7058 3156 90618220
Drug ineffective 38.74 36.70 31 7040 1384267 89237109
Exposure via breast milk 38.55 36.70 12 7059 2303 90619073
Oligohydramnios 38.17 36.70 16 7055 7185 90614191
Eosinophilia 37.73 36.70 25 7046 28508 90592868
Human immunodeficiency virus transmission 36.94 36.70 6 7065 54 90621322

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 909.50 24.13 198 9040 3252 42608845
Foetal exposure during pregnancy 724.27 24.13 299 8939 47012 42565085
Virologic failure 646.05 24.13 154 9084 3840 42608257
Mitochondrial toxicity 605.41 24.13 135 9103 2480 42609617
Eyelid ptosis 544.50 24.13 149 9089 6512 42605585
Viral mutation identified 536.36 24.13 128 9110 3203 42608894
Pathogen resistance 364.29 24.13 124 9114 11326 42600771
Progressive external ophthalmoplegia 349.32 24.13 77 9161 1334 42610763
Diplopia 339.31 24.13 137 9101 20179 42591918
Drug resistance 294.41 24.13 145 9093 34103 42577994
Dandy-Walker syndrome 279.54 24.13 49 9189 229 42611868
Developmental delay 217.81 24.13 62 9176 3120 42608977
Speech disorder developmental 214.17 24.13 57 9181 2228 42609869
Pinealoblastoma 188.27 24.13 33 9205 154 42611943
Volvulus 178.19 24.13 48 9190 1965 42610132
Immune reconstitution inflammatory syndrome 157.54 24.13 65 9173 10078 42602019
Polydactyly 155.66 24.13 39 9199 1195 42610902
Trisomy 21 139.81 24.13 31 9207 551 42611546
Congenital central nervous system anomaly 139.23 24.13 32 9206 673 42611424
Ophthalmoplegia 133.32 24.13 39 9199 2161 42609936
Neurodevelopmental disorder 124.49 24.13 27 9211 431 42611666
Macrocephaly 122.84 24.13 27 9211 460 42611637
Premature baby 101.59 24.13 63 9175 23090 42589007
Portal hypertension 92.78 24.13 36 9202 4751 42607346
Brachydactyly 90.22 24.13 18 9220 186 42611911
Ventricular septal defect 88.53 24.13 34 9204 4365 42607732
Hydrops foetalis 86.80 24.13 23 9215 882 42611215
Attention deficit hyperactivity disorder 84.61 24.13 30 9208 3078 42609019
Ultrasound antenatal screen 82.09 24.13 20 9218 544 42611553
Acquired gene mutation 78.37 24.13 24 9214 1556 42610541
Trisomy 18 78.30 24.13 21 9217 844 42611253
Cleft lip and palate 76.75 24.13 21 9217 911 42611186
Nodular regenerative hyperplasia 74.31 24.13 21 9217 1027 42611070
Atrioventricular septal defect 73.97 24.13 16 9222 252 42611845
Gene mutation 71.42 24.13 23 9215 1758 42610339
Vanishing bile duct syndrome 70.31 24.13 23 9215 1848 42610249
Exposure during pregnancy 69.77 24.13 35 9203 8513 42603584
Stevens-Johnson syndrome 67.36 24.13 48 9190 22130 42589967
Blood HIV RNA increased 61.57 24.13 20 9218 1571 42610526
Congenital neoplasm 60.52 24.13 10 9228 30 42612067
Multiple-drug resistance 59.81 24.13 30 9208 7292 42604805
Blood lactic acid increased 57.16 24.13 30 9208 8009 42604088
Lipoatrophy 55.80 24.13 14 9224 431 42611666
Dyslipidaemia 55.42 24.13 31 9207 9387 42602710
Mitochondrial myopathy 55.24 24.13 12 9226 193 42611904
Portal vein thrombosis 53.63 24.13 24 9214 4525 42607572
Off label use 53.12 24.13 37 9201 638298 41973799
Viral load increased 52.67 24.13 21 9217 2976 42609121
Conjunctivalisation 52.06 24.13 7 9231 0 42612097
Drug ineffective 51.81 24.13 37 9201 630160 41981937
Laryngomalacia 49.27 24.13 12 9226 326 42611771
Speech disorder 45.89 24.13 43 9195 29078 42583019
Fanconi syndrome acquired 45.25 24.13 17 9221 2053 42610044
Ataxia 44.63 24.13 33 9205 16092 42596005
Treatment failure 42.86 24.13 60 9178 62564 42549533
Abortion spontaneous 42.26 24.13 11 9227 393 42611704
Dysphagia 41.57 24.13 64 9174 72655 42539442
Caesarean section 41.38 24.13 16 9222 2090 42610007
Small for dates baby 41.33 24.13 21 9217 5242 42606855
Maternal drugs affecting foetus 41.29 24.13 19 9219 3820 42608277
Varices oesophageal 38.96 24.13 19 9219 4346 42607751
Cerebellar hypoplasia 38.74 24.13 6 9232 10 42612087
Congenital umbilical hernia 38.73 24.13 10 9228 346 42611751
Pre-eclampsia 38.45 24.13 7 9231 42 42612055
Osteoporosis 37.91 24.13 29 9209 14877 42597220
Product residue present 36.75 24.13 16 9222 2825 42609272
Bone metabolism disorder 36.32 24.13 9 9229 263 42611834
Osteoporotic fracture 35.19 24.13 13 9225 1498 42610599
Nephropathy toxic 34.79 24.13 29 9209 16809 42595288
Cystitis noninfective 34.35 24.13 10 9228 544 42611553
HIV peripheral neuropathy 34.22 24.13 6 9232 28 42612069
Toxic epidermal necrolysis 33.77 24.13 35 9203 26715 42585382
Hepatic steatosis 32.51 24.13 31 9207 21417 42590680
Pain 32.01 24.13 7 9231 244841 42367256
Retroperitoneal disorder 31.91 24.13 6 9232 44 42612053
Blood triglycerides abnormal 31.55 24.13 8 9230 257 42611840
Low set ears 30.73 24.13 9 9229 500 42611597
Human immunodeficiency virus transmission 30.25 24.13 6 9232 60 42612037
Fall 30.06 24.13 7 9231 234513 42377584
Death neonatal 29.08 24.13 8 9230 354 42611743
Low birth weight baby 28.96 24.13 21 9217 9934 42602163
Immune recovery uveitis 28.46 24.13 6 9232 83 42612014
Meningitis cryptococcal 28.43 24.13 14 9224 3269 42608828
Renal aneurysm 28.30 24.13 7 9231 203 42611894
Congenital nose malformation 28.04 24.13 7 9231 211 42611886
Hepatomegaly 27.95 24.13 22 9216 11763 42600334
Synostosis 27.30 24.13 6 9232 102 42611995
Protrusion tongue 27.28 24.13 7 9231 236 42611861
Hepatic cirrhosis 27.09 24.13 27 9211 19675 42592422
Kaposi's sarcoma 26.78 24.13 9 9229 786 42611311
Alanine aminotransferase increased 26.60 24.13 59 9179 88347 42523750
Aspartate aminotransferase increased 26.09 24.13 54 9184 77109 42534988
Treatment noncompliance 25.62 24.13 36 9202 37636 42574461
Glycosuria 25.47 24.13 10 9228 1360 42610737
Loss of anatomical alignment after fracture reduction 25.36 24.13 4 9234 8 42612089
HIV infection 24.69 24.13 10 9228 1475 42610622
Molluscum contagiosum 24.62 24.13 7 9231 350 42611747
Fracture malunion 24.46 24.13 4 9234 11 42612086
Blood insulin increased 24.39 24.13 7 9231 362 42611735
Osteonecrosis 24.17 24.13 23 9215 15842 42596255

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 1181.80 23.61 230 12048 4294 110572727
Virologic failure 1034.91 23.61 209 12069 4743 110572278
Viral mutation identified 872.89 23.61 178 12100 4241 110572780
Mitochondrial toxicity 762.05 23.61 151 12127 3094 110573927
Drug resistance 729.10 23.61 263 12015 56111 110520910
Eyelid ptosis 535.96 23.61 148 12130 13179 110563842
Pathogen resistance 490.34 23.61 147 12131 17525 110559496
Progressive external ophthalmoplegia 406.32 23.61 78 12200 1342 110575679
Immune reconstitution inflammatory syndrome 365.30 23.61 115 12163 16111 110560910
Diplopia 335.22 23.61 138 12140 41756 110535265
Stevens-Johnson syndrome 262.24 23.61 120 12158 46781 110530240
Foetal exposure during pregnancy 241.19 23.61 70 12208 7435 110569586
Caesarean section 222.38 23.61 76 12202 13741 110563280
Acquired gene mutation 220.65 23.61 53 12225 2701 110574320
Stillbirth 207.13 23.61 55 12223 4209 110572812
Portal hypertension 197.60 23.61 62 12216 8575 110568446
Abortion spontaneous 186.21 23.61 86 12192 34196 110542825
Exposure during pregnancy 165.94 23.61 142 12136 167282 110409739
Maternal exposure during pregnancy 142.72 23.61 158 12120 254725 110322296
Viral load increased 137.80 23.61 38 12240 3352 110573669
Ophthalmoplegia 136.06 23.61 38 12240 3512 110573509
Ultrasound antenatal screen 130.84 23.61 27 12251 679 110576342
Pregnancy 129.75 23.61 77 12201 50990 110526031
Hydrops foetalis 128.12 23.61 27 12251 754 110576267
Conjunctivalisation 122.57 23.61 16 12262 9 110577012
Trisomy 18 116.55 23.61 24 12254 597 110576424
Cleft lip and palate 112.62 23.61 24 12254 708 110576313
Nephropathy toxic 110.12 23.61 56 12222 27422 110549599
Toxic epidermal necrolysis 100.24 23.61 68 12210 56659 110520362
Blood HIV RNA increased 91.12 23.61 25 12253 2163 110574858
Lipoatrophy 87.45 23.61 19 12259 615 110576406
Alanine aminotransferase increased 86.07 23.61 104 12174 183669 110393352
Dyslipidaemia 83.39 23.61 39 12239 15926 110561095
Aspartate aminotransferase increased 80.65 23.61 94 12184 159842 110417179
Maternal drugs affecting foetus 79.20 23.61 21 12257 1596 110575425
Proteinuria 78.00 23.61 51 12227 39967 110537054
Vanishing bile duct syndrome 77.73 23.61 24 12254 3144 110573877
Postpartum sepsis 77.70 23.61 10 12268 4 110577017
Abortion induced 76.45 23.61 30 12248 7989 110569032
Pulmonary tuberculosis 76.05 23.61 31 12247 9108 110567913
Premature delivery 74.69 23.61 45 12233 30587 110546434
Retinoblastoma 72.84 23.61 12 12266 80 110576941
Fat tissue increased 71.88 23.61 18 12260 1090 110575931
CD4 lymphocytes decreased 70.73 23.61 22 12256 2952 110574069
Treatment noncompliance 70.35 23.61 61 12217 72929 110504092
Hepatomegaly 69.75 23.61 38 12240 21376 110555645
Ulcerative keratitis 68.10 23.61 24 12254 4742 110572279
Nodular regenerative hyperplasia 64.98 23.61 18 12260 1613 110575408
Pain 62.03 23.61 15 12263 954940 109622081
Portal vein thrombosis 58.93 23.61 24 12254 7034 110569987
Blood lactic acid increased 56.93 23.61 30 12248 15791 110561230
Uveal prolapse 56.74 23.61 7 12271 0 110577021
Tuberculosis 56.39 23.61 31 12247 17743 110559278
Malaria 54.46 23.61 12 12266 415 110576606
Acute HIV infection 54.37 23.61 9 12269 62 110576959
Mitochondrial myopathy 53.73 23.61 12 12266 442 110576579
Immune reconstitution inflammatory syndrome associated tuberculosis 53.11 23.61 14 12264 1040 110575981
Multiple-drug resistance 53.09 23.61 27 12251 13208 110563813
Hepatic cytolysis 53.02 23.61 46 12232 55007 110522014
Eyelid scar 52.97 23.61 7 12271 5 110577016
Glycosuria 52.40 23.61 17 12261 2613 110574408
Pre-eclampsia 51.03 23.61 23 12255 8627 110568394
Meningitis cryptococcal 49.60 23.61 19 12259 4743 110572278
Product residue present 49.36 23.61 18 12260 3923 110573098
Dandy-Walker syndrome 49.15 23.61 8 12270 49 110576972
Dysphagia 48.88 23.61 72 12206 153528 110423493
Varices oesophageal 48.41 23.61 21 12257 7194 110569827
Anaemia 47.59 23.61 151 12127 546935 110030086
Drug ineffective 47.24 23.61 60 12218 1520480 109056541
Pinealoblastoma 47.17 23.61 8 12270 65 110576956
Fanconi syndrome acquired 46.12 23.61 16 12262 3018 110574003
Conjunctival hyperaemia 45.87 23.61 19 12259 5812 110571209
HIV infection 45.63 23.61 13 12265 1290 110575731
Gamma-glutamyltransferase increased 44.98 23.61 44 12234 61265 110515756
Blindness 44.67 23.61 35 12243 36324 110540697
Hepatotoxicity 43.74 23.61 44 12234 63356 110513665
Premature baby 42.22 23.61 17 12261 4838 110572183
Off label use 41.78 23.61 64 12214 1500121 109076900
Eyelid oedema 41.33 23.61 24 12254 15238 110561783
Ventricular septal defect 38.39 23.61 10 12268 709 110576312
Oligohydramnios 38.27 23.61 15 12263 3979 110573042
Rash maculo-papular 38.00 23.61 44 12234 74178 110502843
Drug reaction with eosinophilia and systemic symptoms 37.63 23.61 46 12232 82049 110494972
Hepatic steatosis 37.61 23.61 36 12242 48795 110528226
Neutropenia neonatal 37.26 23.61 6 12272 34 110576987
HIV peripheral neuropathy 37.26 23.61 6 12272 34 110576987
Osteoporosis 37.02 23.61 47 12231 87105 110489916
Genotype drug resistance test positive 35.97 23.61 11 12267 1395 110575626
Retroperitoneal disorder 35.92 23.61 6 12272 44 110576977
Bone metabolism disorder 35.38 23.61 9 12269 581 110576440
Premature labour 34.73 23.61 18 12260 9154 110567867
Fatigue 33.67 23.61 52 12226 1215906 109361115
Gene mutation 33.29 23.61 13 12265 3416 110573605
Lactic acidosis 33.18 23.61 46 12232 92765 110484256
Fall 32.80 23.61 13 12265 603469 109973552
Developmental delay 31.35 23.61 10 12268 1455 110575566
Splenomegaly 31.00 23.61 24 12254 24474 110552547
Progressive multifocal leukoencephalopathy 30.60 23.61 24 12254 24932 110552089
Blood triglycerides abnormal 30.52 23.61 8 12270 581 110576440
Toxoplasmosis 30.46 23.61 12 12266 3227 110573794
Renal aneurysm 30.42 23.61 7 12271 295 110576726
Anaemia neonatal 30.39 23.61 5 12273 33 110576988
Molluscum contagiosum 29.96 23.61 8 12270 624 110576397
Astrocytoma malignant 29.89 23.61 5 12273 37 110576984
Strabismus 29.56 23.61 12 12266 3487 110573534
Pyrexia 29.34 23.61 185 12093 898080 109678941
Immune recovery uveitis 29.34 23.61 6 12272 144 110576877
Hyperplasia adrenal 29.12 23.61 5 12273 44 110576977
Meningitis tuberculous 28.50 23.61 9 12269 1269 110575752
Placental insufficiency 28.38 23.61 9 12269 1285 110575736
Retinal vasculitis 28.06 23.61 10 12268 2039 110574982
Loss of anatomical alignment after fracture reduction 28.03 23.61 4 12274 8 110577013
Hepatic cirrhosis 27.97 23.61 36 12242 67590 110509431
Abdominal discomfort 27.95 23.61 5 12273 393853 110183168
Osteoporotic fracture 27.75 23.61 13 12265 5324 110571697
Cytomegalovirus chorioretinitis 27.02 23.61 14 12264 7114 110569907
Speech disorder developmental 27 23.61 8 12270 911 110576110
Portal venous gas 26.49 23.61 7 12271 525 110576496
Cachexia 26.37 23.61 17 12261 12988 110564033
Hereditary optic atrophy 25.92 23.61 5 12273 88 110576933
Tuberculoma of central nervous system 25.46 23.61 7 12271 610 110576411
Product use in unapproved indication 25.36 23.61 9 12269 447368 110129653
Lipase increased 25.18 23.61 19 12259 18653 110558368
Hyperlactacidaemia 25.04 23.61 14 12264 8272 110568749
Portal hypertensive gastropathy 24.96 23.61 9 12269 1899 110575122
Lymphadenopathy 24.88 23.61 33 12245 63802 110513219
Chronic hepatitis C 24.57 23.61 7 12271 694 110576327
Kaposi's sarcoma 24.56 23.61 7 12271 695 110576326
Osteonecrosis 24.34 23.61 24 12254 33717 110543304
Hepatitis 24.12 23.61 39 12239 90015 110487006
Drug interaction 23.67 23.61 114 12164 500069 110076952

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AG01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Non-nucleoside reverse transcriptase inhibitors
ATC J05AR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR07 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175460 Non-Nucleoside Analog
FDA EPC N0000175463 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190118 Cytochrome P450 3A Inducers
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
MeSH PA D019380 Anti-HIV Agents
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:53756 HIV-1 reverse transcriptase inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

J05AG Non-nucleoside reverse transcriptase inhibitors 5 drugs
delavirdinedoravirineefavirenzetravirinerilpivirine
J05AR Antivirals for treatment of HIV infections, combinations 19 drugs
abacaviratazanavirbictegravircobicistatdarunavirdolutegravirdoravirineefavirenzelvitegraviremtricitabinelamivudinelopinavir show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Lyell's toxic epidermal necrolysis, subepidermal type contraindication 23067006
Viral hepatitis C contraindication 50711007 DOID:1883
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Chronic type B viral hepatitis contraindication 61977001
Stevens-Johnson syndrome contraindication 73442001 DOID:0050426
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Rhabdomyolysis contraindication 240131006
Eruption of skin contraindication 271807003 DOID:0050486
Breastfeeding (mother) contraindication 413712001
Prevention of HIV Infection after Exposure contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.01 acidic
pKa2 2.45 Basic
pKa3 1.74 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
400MG VIRAMUNE XR BOEHRINGER INGELHEIM N201152 March 25, 2011 DISCN TABLET, EXTENDED RELEASE ORAL 8460704 March 12, 2029 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR Ki 6.40 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 7.10 WOMBAT-PK
Pol polyprotein Enzyme IC50 7 CHEMBL
Reverse transcriptase Enzyme IC50 6.30 CHEMBL
Reverse transcriptase protein Enzyme Ki 5.40 CHEMBL

External reference:

IDSource
4020991 VUID
N0000148461 NUI
D00435 KEGG_DRUG
220988-26-1 SECONDARY_CAS_RN
4020991 VANDF
C0132326 UMLSCUI
CHEBI:63613 CHEBI
NEV PDB_CHEM_ID
CHEMBL57 ChEMBL_ID
DB00238 DRUGBANK_ID
D019829 MESH_DESCRIPTOR_UI
4463 PUBCHEM_CID
12676 IUPHAR_LIGAND_ID
6815 INN_ID
99DK7FVK1H UNII
224890 RXNORM
175112 MMSL
5168 MMSL
6060 MMSL
d04029 MMSL
006062 NDDF
108704001 SNOMEDCT_US
386898005 SNOMEDCT_US
725663003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4050 TABLET 200 mg ORAL ANDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 0378-4890 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 30 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 31722-505 TABLET 200 mg ORAL ANDA 28 sections
Nevirapine Human Prescription Drug Label 1 33342-004 TABLET 200 mg ORAL ANDA 28 sections
NEVIRAPINE Human Prescription Drug Label 1 33342-238 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 29 sections
NEVIRAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-131 TABLET 200 mg ORAL ANDA 27 sections
NEVIRAPINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-131 TABLET 200 mg ORAL ANDA 27 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53104-0166 TABLET 200 mg ORAL ANDA 26 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-0680 TABLET 200 mg ORAL ANDA 29 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 53808-0808 TABLET 200 mg ORAL NDA 31 sections
nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 53808-1069 TABLET 200 mg ORAL ANDA 28 sections
Viramune HUMAN PRESCRIPTION DRUG LABEL 1 54868-6370 TABLET, EXTENDED RELEASE 400 mg ORAL NDA 29 sections
Nevirapine HUMAN PRESCRIPTION DRUG LABEL 1 65162-209 TABLET 200 mg ORAL ANDA 27 sections
Nevirapine Human Prescription Drug Label 1 65862-027 TABLET 200 mg ORAL ANDA 27 sections
Nevirapine Human Prescription Drug Label 1 65862-057 SUSPENSION 50 mg ORAL ANDA 29 sections